frequency of IFNg-producing CD8+ CTL in the elispot assay in response to either CML or CML/DC was observed after vaccination.
With this small-scale phase I study, we have shown that intradermal vaccination with in vitro generated autologous CML/ DC in patients with late chronic phase CML is feasible, without adverse side effects. It proved possible to mount an immune response in these pretreated patients, as demonstrated by the strong DTH reaction against KLH. Most promising was the finding in 2/3 patients of a DTH reaction against autologous CML/DC and uncultured CML cells and in one of these patients of a measurable leukemia-specific response up to 20 months after the last vaccination. It is remarkable that in the presence of such a large tumor burden, an appreciable antileukemia immune response could be induced. Accrual for this study was stopped prematurely because of the availability of the very effective bcr/abl-specific tyrosine kinase inhibitor STI571 (Gleevec) for IFN-a-resistant CML. 10 However, the majority of CML patients who achieve complete cytogenetic responses after STI are still bcr/abl PCR positive, 11 indicating the presence of minimal residual disease (MRD). Also, the emergence of resistance mechanisms against STI571 has been reported. 12 Therefore, adjuvant immunotherapy is still a viable option in the management of CML, particularly in patients with MRD after STI571 treatment. Our study indicates that autologous CML/DCbased vaccination may be a valid approach in this regard. 
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TO THE EDITOR
The simultaneous occurrence of CML and MM, an extremely rare event that has been reported in only five cases, 1 raises the question of a common clonal origin. So far, no evidence has been obtained supporting such a hypothesis. In two of the reported cases the diseases occurred simultaneously, 1,2 in one patient CML antedated MM, 3 and in the other two CML developed after MM, 4,5 but in none of the cases a common cellular origin was demonstrated. We here report on a patient with CML and MM whose malignant cell clones were characterized by cytogenetic and interphase fluorescence in situ hybridization (FISH) analysis and whose bone marrow (BM) cells were expanded in vitro to search for a common progenitor of CML and MM cells.
A 66-year-old white male presented with an asymptomatic soft tissue-like formation along the lateral part of the right sixth rib. In accordance with the patient's history of a recent accident, the results of computed tomography and magnetic resonance imaging were suggestive of a post-traumatic lesion. A whole-body technetium scan revealed hyperactivity within this area, but no other pathologic skeletal findings. Further examination showed marked splenomegaly and abnormal blood cell counts (WBC 171 Â 10 9 /l, 45% segmented neutrophils, 14% band forms, 11% metamyelocytes, 9% myelocytes, 4% promyelocytes, 7% eosinophils, 2% basophils, 6% lymphocytes and 2% monocytes, Hb 10.5 g/dl, and platelets 484 Â 10 9 /l). A BM aspirate was characterized by high cellularity with marked myeloid hyperplasia, increased number of eosinophils, numerous megakaryocytes, 3% mature plasma cells, but no increase in blast cells. The neutrophil alkaline phosphatase score was reduced and serum LDH was increased to 910 U/l. Cytogenetic analysis revealed Ph 1 chromosome in all of the 50 metaphases obtained from the bone marrow: 46, XY, t(9;22)(q34;q11). RT-PCR and mRNA amplification of MNC from peripheral blood as well as BM showed the fusion of bcr and abl genes. After establishing the diagnosis of CML cytoreductive therapy was initiated with hydroxyurea, and then therapy was switched to interferon-a (5 million units/m 2 /day s.c.). After 3 weeks, symptoms of renal failure developed. A kidney biopsy revealed deposition of IgGk light chains within glomerular membranes. Immunofixation also showed monoclonal IgGk light chains in serum and urine. A new bone marrow biopsy indicated a decrease of myeloid hyperplasia and an increase of CD79a, VS38c-positive plasma cells (15%), expressing monotypic k light chains. These findings indicated the coexistence of CML and MM and the patient was further treated with prednisolone and melphalan. This resulted in the reduction of plasma cells; the renal function, however, continued to deteriorate and hemodialysis had to be installed. After 2 years, CML remains in chronic phase; the lesion in the right sixth rib, however, has progressed and an infiltration with malignant plasma cells was found. The patient is currently treated with intermittent courses of prednisolone for MM and busulfan for CML.
To investigate clonal chromosomal abnormalities among distinct BM cell fractions, FISH studies of BM mononuclear and granulocytic cells were performed. BM cells were separated into granulocytic and mononuclear cells, fixed with Carnoy's solution and stored at À801C. FISH analyses were performed as previously described. 6 Three-color immunofluorescence assays were applied, combining two differentially labeled FISH probes with staining of cytoplasmic immunoglobulin light chains (goat-anti-human k or l light-chain antibody conjugated with 7-amino-4-methylcoumarin-3-acetic acid) (Vector Laboratories, Burlingame, CA, USA). Prehybridization, hybridization and posthybridization washes were performed according to the standard protocol. FISH probes used in this study included the bcr-abl translocation probe and the rb-1 probe specific for 13q14 (Vysis Inc., Downers Grove, IL, USA).
Immunophenotyping and in vitro expansion of BM cells: Immunophenotypic characterization of BM cells was performed by flow cytometry using a FACS Calibur system (Becton Dickinson, San Jose, CA, USA). Conjugated antibodies against the following surface antigens were used: CD3, CD10, CD13, CD14, CD19, CD22, CD23, CD33, CD34, CD38, CD45, CD56, CD117 (Becton Dickinson, San Jose, CA, USA); CD21, CD44, CD49d, CD106 (Serotec, Oxfordshire, UK); CD138 (IQP, Groningen, NL, USA). Expansion of BM cells was performed in an autologous coculture system, using BM fibroblasts to support the survival of progenitor cells. Several cultures were supplemented with IL-6 or with GM-CSF to enhance proliferation of myeloma cells and myeloid progenitor cells, respectively. After 4 weeks in coculture, five cell lines were established and continuously grown, independently from fibroblasts.
The results revealed, in agreement with the cytogenetic report, a bcr-abl cohybridization signal in the majority of granulocytic cells (Table 1, Figure 1a) . k-positive plasma cells were screened for the presence of chromosomal aneuploidy. As demonstrated in Table 1 and Figure 1b , the plasma cells exhibited with an rb-1-specific probe a deletion of 13q14, whereas diploid results were obtained with centromeric probes for chromosomes 9, 11, 17 and locusspecific probes for 11q13 (CCDN-1) and 17p13 (p53) (data not shown). There was no evidence for a bcr-abl cohybridization signal in k-positive plasma cells. In contrast, k-negative BM cells were found to carry a bcr-abl fusion signal, but these cells were diploid for 13q14 by FISH. A small population of l-positive plasma cells was observed to be normal with both the rb-1 and bcr-abl probes, suggesting that they corresponded to residual normal plasma cells. While in previous studies CML cells and malignant plasma cells could not be discriminated cytogenetically at a single cell level, 1 FISH analysis has now permitted to distinguish clearly between the two malignant cell populations in our patient.
The association of MM and chronic myeloproliferative disorders has been considered to be mostly coincidental; however, an origin from a common precursor cell could not be ruled out. Table 1 Interphase FISH analysis of BM cells To possibly detect cells bearing markers of myeloid and plasmacytic cells, FACS analysis was performed. A major part of BM cells expressed myeloid markers (CD33: 75%; CD13: 63%; CD117: 9%), while 3% of the cells were positive for plasma cell antigens (CD38, CD138). Within the CD138 + population 6% coexpressed CD117 and CD13, and 4% coexpressed CD117 and CD33. These populations, however, were too small to identify bcr-abl-positive cells. The attempt to expand a potential BM progenitor of CML and MM cells resulted in five cell lines, which appeared morphologically as immature myeloma cells (large size, perinuclear clear zone, Russel bodies and giant multinucleated cells), and express the following surface markers: CD38 (88%), CD19 (89%), CD10 (67%), CD33 (16%), CD13 (8%) according to FACS analysis. A small fraction of these cells (o1%) was found to coexpress surface markers of myeloid progenitors (CD13, CD33, CD117) and markers characteristic for plasma cells (CD38, CD138). FISH analysis, however, did not provide evidence for a bcr-abl fusion signal and chromosome 13q14 was found to be diploid.
It is important to note that various surface antigens can be aberrantly expressed on myeloma cells, therefore, the expression of myeloid markers on BM myeloma cell and myeloma cell lines does not provide sufficient evidence for the presence of a common stem cell for CML and MM. This assumption is supported by the fact that the earliest candidate for a myeloma stem cell is a preswitched antigen experienced B cell, while CML arises from an early hematopoietic precursor cell. On the other hand, the lack of complete lineage fidelity is a known issue in CML and is demonstrated by the detection of Ig rearrangements in the leukemic cells of some cases and by the occurrence of lymphoid blast crisis. Also, some B cells in CML patients were shown to harbor the bcr-abl translocation. 7 Therefore, in the patient reported here, where MM followed CML, the question arises on whether a transformation event occurred in a bcr-abl + B cell being attributed to the CML clone. By FISH analysis of BM cells and cell lines, we were able to show that this is not the case. This argues against an essential role of bcr-abl fusion in the emergence of the plasma cell clone.
Taken together, our data suggest the coincidence of two distinct BM clonal disorders in our patient and may exclude a role for bcrabl fusion in the generation of plasma cell clones in patients with coexisting CML and MM. 
The importance of angiogenesis for growth and viability of solid tumors has been established. Knowledge on these relations in hematological tumors, however, is circumstantial. Tumor microvessel density predicts a risk of progression in multiple myeloma, 1 is correlated with progression stages in both B-cell non-Hodgkin's lymphomas 2 and matches in step with the growth of acute leukemias and myelodysplastic syndromes.
Angiogenesis is involved in the pathogenesis of B-cell chronic lymphocytic leukemia (B-cell CLL). 3 The two most potent angiogenesis inducers, namely vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2) are both involved in B-cell CLL. VEGF, present in both the patients' serum and leukemic cells is related to poor prognosis, while FGF-2 expression by leukemic cells is associated with advanced disease and resistance to fludarabine.
Tumor cells are surrounded by an infiltrate of inflammatory cells, namely lymphocytes, neutrophils, macrophages and mast cells (MC), which communicate via a complex network of intercellular signaling pathways mediated by surface adhesion molecules, cytokines and their receptors. MC density is highly correlated with the extent of both normal and pathological angiogenesis, such as that in chronic inflammatory diseases and tumors.
